JP2007501800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501800A5 JP2007501800A5 JP2006522776A JP2006522776A JP2007501800A5 JP 2007501800 A5 JP2007501800 A5 JP 2007501800A5 JP 2006522776 A JP2006522776 A JP 2006522776A JP 2006522776 A JP2006522776 A JP 2006522776A JP 2007501800 A5 JP2007501800 A5 JP 2007501800A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- alkyl
- group
- lower alkyl
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 49
- 125000004432 carbon atoms Chemical group C* 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 17
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 16
- 206010006895 Cachexia Diseases 0.000 claims 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000011780 sodium chloride Substances 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 9
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 7
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000005466 alkylenyl group Chemical group 0.000 claims 5
- 125000001246 bromo group Chemical group Br* 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- -1 fibrates Substances 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- LIEMBEWXEZJEEZ-INEUFUBQSA-N (2R,3R)-4-(6-aminopurin-9-yl)-2,3-dihydroxybutanoic acid Chemical compound NC1=NC=NC2=C1N=CN2C[C@@H](O)[C@@H](O)C(O)=O LIEMBEWXEZJEEZ-INEUFUBQSA-N 0.000 claims 1
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9E,12E)-N-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 claims 1
- KAJZGRFYZKWYDX-VQHVLOKHSA-N (E)-3-methyl-4-phenylbut-3-enamide Chemical compound NC(=O)CC(/C)=C/C1=CC=CC=C1 KAJZGRFYZKWYDX-VQHVLOKHSA-N 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims 1
- SYHDSBBKRLVLFF-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-[4-[2-(diethylamino)ethoxy]phenyl]-1-(4-methylphenyl)ethanol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC(C)=CC=1)CC1=CC=C(Cl)C=C1 SYHDSBBKRLVLFF-UHFFFAOYSA-N 0.000 claims 1
- UNFGQCCHVMMMRF-UHFFFAOYSA-N 2-phenylbutanamide Chemical compound CCC(C(N)=O)C1=CC=CC=C1 UNFGQCCHVMMMRF-UHFFFAOYSA-N 0.000 claims 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- FMTFZYKYVZBISL-HUVRVWIJSA-N Azacosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](N(C)CCCN(C)C)[C@@]1(C)CC2 FMTFZYKYVZBISL-HUVRVWIJSA-N 0.000 claims 1
- 229950005866 Azacosterol Drugs 0.000 claims 1
- CJAVTWRYCDNHSM-UHFFFAOYSA-N Benfluorex Chemical compound C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 229960004203 Carnitine Drugs 0.000 claims 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 208000009863 Chronic Kidney Failure Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 229960000633 Dextran Sulfate Drugs 0.000 claims 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 1
- 206010021425 Immune system disease Diseases 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 229960003104 Ornithine Drugs 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N Probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 1
- 206010038444 Renal failure chronic Diseases 0.000 claims 1
- 208000001076 Sarcopenia Diseases 0.000 claims 1
- 229950005498 TRIPARANOL Drugs 0.000 claims 1
- 229940036555 Thyroid hormones Drugs 0.000 claims 1
- WRCITXQNXAIKLR-UHFFFAOYSA-N Tiadenol Chemical compound OCCSCCCCCCCCCCSCCO WRCITXQNXAIKLR-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960001264 benfluorex Drugs 0.000 claims 1
- 229950008586 benzalamide Drugs 0.000 claims 1
- 229940076810 beta Sitosterol Drugs 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 201000003883 cystic fibrosis Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N icosa-5,8,11,14,17-pentaenoic acid Chemical compound CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960001518 levocarnitine Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 229950008446 melinamide Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims 1
- 229960000903 pantethine Drugs 0.000 claims 1
- 235000008975 pantethine Nutrition 0.000 claims 1
- 239000011581 pantethine Substances 0.000 claims 1
- SDVVLIIVFBKBMG-UHFFFAOYSA-N penta-2,4-dienoic acid Chemical group OC(=O)C=CC=C SDVVLIIVFBKBMG-UHFFFAOYSA-N 0.000 claims 1
- 229940083256 peripheral vasodilators Nicotinic acid and derivatives Drugs 0.000 claims 1
- 229940096698 plain lipid modifying Nicotinic acid and derivatives Drugs 0.000 claims 1
- 229940096700 plain lipid modifying drugs Fibrates Drugs 0.000 claims 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 claims 1
- 229960003912 probucol Drugs 0.000 claims 1
- 229950005143 sitosterol Drugs 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000005495 thyroid hormone Substances 0.000 claims 1
- 229960000822 tiadenol Drugs 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N β-Sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N γ-Oryzanol Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49313803P | 2003-08-07 | 2003-08-07 | |
| US53373403P | 2003-12-31 | 2003-12-31 | |
| PCT/US2004/025564 WO2005013949A2 (en) | 2003-08-07 | 2004-08-06 | Method for treating cachexia with retinoid ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007501800A JP2007501800A (ja) | 2007-02-01 |
| JP2007501800A5 true JP2007501800A5 (pl) | 2007-09-20 |
Family
ID=34138739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522776A Pending JP2007501800A (ja) | 2003-08-07 | 2004-08-06 | レチノイドリガンドを用いて悪液質を処置するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1653939A2 (pl) |
| JP (1) | JP2007501800A (pl) |
| AU (1) | AU2004263156B2 (pl) |
| CA (1) | CA2535260A1 (pl) |
| WO (1) | WO2005013949A2 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1937244T (pt) | 2005-09-30 | 2018-11-07 | Io Therapeutics Llc | Tratamento do cancro com agonistas específicos de rxr |
| WO2008020034A1 (en) * | 2006-08-16 | 2008-02-21 | Action Medicines, S.L. | Use of 2,5-dihydroxybenzene derivatives for the treatment of hemangiomas or hemangioblastomas |
| US20120115912A1 (en) * | 2009-07-10 | 2012-05-10 | Landreth Gary E | Rxr agonist compounds and methods |
| EP2556827A1 (en) * | 2011-08-11 | 2013-02-13 | Acadia Pharmaceuticals Inc. | Treatment of neurodegenerative diseases |
| EP2910549A1 (en) * | 2011-09-15 | 2015-08-26 | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University | 1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalene derivatives useful as rxr modulators for treating alzheimer's disease and cancer |
| CA2858882C (en) | 2011-12-13 | 2021-02-02 | Trustees Of Dartmouth College | Autoimmune disorder treatment using rxr agonists |
| EP3071205B1 (en) | 2013-11-18 | 2020-02-05 | Forma Therapeutics, Inc. | Benzopiperazine compositions as bet bromodomain inhibitors |
| WO2015074064A2 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
| IL261669B2 (en) * | 2016-03-10 | 2023-12-01 | Io Therapeutics Inc | A combination of thyroid hormones and an RXR agonist for the treatment of autoimmune diseases |
| US10835507B2 (en) * | 2016-03-10 | 2020-11-17 | Io Therapeutics, Inc. | Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones |
| US10238655B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Dihydroindene and tetrahydronaphthalene compounds |
| US10231947B2 (en) | 2017-01-23 | 2019-03-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Isochroman compounds and methods of use thereof |
| US10238626B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| US11517549B2 (en) | 2017-09-20 | 2022-12-06 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| MX2024006978A (es) | 2021-12-07 | 2024-07-19 | Io Therapeutics Inc | Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+. |
| CA3242047A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist in treating drug resistant her2+ cancers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6320074B1 (en) * | 1992-04-22 | 2001-11-20 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
| ES2133798T3 (es) * | 1994-08-10 | 1999-09-16 | Hoffmann La Roche | Ligandos del receptor x del acido retinoico. |
| IL116259A (en) * | 1994-12-19 | 2000-07-16 | American Cyanamid Co | Analogs of 9-cis retinoic acid and their use |
| US5917082A (en) * | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
| US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
-
2004
- 2004-08-06 CA CA002535260A patent/CA2535260A1/en not_active Abandoned
- 2004-08-06 WO PCT/US2004/025564 patent/WO2005013949A2/en active Application Filing
- 2004-08-06 JP JP2006522776A patent/JP2007501800A/ja active Pending
- 2004-08-06 EP EP04780406A patent/EP1653939A2/en not_active Withdrawn
- 2004-08-06 AU AU2004263156A patent/AU2004263156B2/en not_active Ceased